纳武利尤单抗用于酪氨酸激酶抑制剂敏感的转移性肾细胞癌患者的转换维持治疗的有效性和实用性：来自NIVOSWITCH研究的经验教训 - Suppr

Suppr

超能文献

Validity and utility of switch-maintenance therapy with nivolumab in tyrosine kinase inhibitor-sensitive patients with metastatic renal cell carcinoma: learning from NIVOSWITCH.

作者信息

Kato Taigo, Nonomura Norio

机构信息

Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.

出版信息

Transl Androl Urol. 2024 Jul 31;13(7):1333-1335. doi: 10.21037/tau-24-14. Epub 2024 Jul 16.

DOI:10.21037/tau-24-14

PMID:39100829

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11291407/

Abstract

摘要

相似文献

Validity and utility of switch-maintenance therapy with nivolumab in tyrosine kinase inhibitor-sensitive patients with metastatic renal cell carcinoma: learning from NIVOSWITCH.纳武利尤单抗用于酪氨酸激酶抑制剂敏感的转移性肾细胞癌患者的转换维持治疗的有效性和实用性：来自NIVOSWITCH研究的经验教训

Transl Androl Urol. 2024 Jul 31;13(7):1333-1335. doi: 10.21037/tau-24-14. Epub 2024 Jul 16.

Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).纳武利尤单抗在转移性肾细胞癌患者中酪氨酸激酶抑制剂诱导后的维持治疗：德国癌症学会多学科肾癌工作组（NIVOSWITCH；AIO-NZK-0116ass）的一项随机临床试验。

Eur Urol. 2023 Dec;84(6):571-578. doi: 10.1016/j.eururo.2023.09.004. Epub 2023 Sep 26.

[First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].晚期肾细胞癌的一线治疗：一项随机II期研究，旨在比较晚期或转移性肾细胞癌患者在治疗三个月后疾病稳定时，酪氨酸激酶抑制剂早期换用纳武利尤单抗与继续使用酪氨酸激酶抑制剂治疗的效果（NIVOSWITCH - AUO的AN 38/15）

Urologe A. 2017 Apr;56(4):509-511. doi: 10.1007/s00120-017-0343-2.

Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.纳武单抗治疗后转移性肾细胞癌对酪氨酸激酶抑制剂恢复敏感性：一例报告

Oncol Lett. 2019 Apr;17(4):4011-4015. doi: 10.3892/ol.2019.10027. Epub 2019 Feb 8.

Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma.从酪氨酸激酶抑制剂转换为免疫检查点抑制剂的转换疗法的有效性：在转移性肾细胞癌患者中建立治疗策略对生物标志物的需求。

Transl Androl Urol. 2024 Apr 30;13(4):631-634. doi: 10.21037/tau-23-647. Epub 2024 Apr 12.

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.卡博替尼联合纳武利尤单抗治疗晚期肾细胞癌的研究进展。

Target Oncol. 2022 Mar;17(2):193-201. doi: 10.1007/s11523-022-00866-1. Epub 2022 Feb 17.

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.纳武利尤单抗、纳武利尤单抗-伊匹木单抗和VEGFR酪氨酸激酶抑制剂作为转移性透明细胞肾细胞癌的一线治疗（BIONIKK）：一项生物标志物驱动、开放标签、非对照、随机2期试验。

Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4.

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.联合抗血管生成酪氨酸激酶抑制和抗 PD-1 免疫治疗转移性肾细胞癌：安全性、耐受性和临床结局的回顾性分析。

Cancer Med. 2021 Apr;10(7):2341-2349. doi: 10.1002/cam4.3812. Epub 2021 Mar 1.

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.转移性肾细胞癌的真实世界治疗方案和结局。

PLoS One. 2023 Nov 22;18(11):e0294039. doi: 10.1371/journal.pone.0294039. eCollection 2023.

Systemic therapy in metastatic renal cell carcinoma.转移性肾细胞癌的全身治疗

World J Urol. 2017 Feb;35(2):179-188. doi: 10.1007/s00345-016-1868-5. Epub 2016 Jun 9.

本文引用的文献

Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.免疫检查点抑制剂联合治疗晚期肾细胞癌的疗效和毒性：系统评价和网络荟萃分析。

Front Immunol. 2024 Feb 8;15:1255577. doi: 10.3389/fimmu.2024.1255577. eCollection 2024.

Eur Urol. 2023 Dec;84(6):571-578. doi: 10.1016/j.eururo.2023.09.004. Epub 2023 Sep 26.

The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.免疫检查点抑制剂与酪氨酸激酶抑制剂联合治疗晚期或转移性肾细胞癌的疗效和安全性：一项多中心回顾性真实世界队列研究

Cancers (Basel). 2023 Feb 2;15(3):947. doi: 10.3390/cancers15030947.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.欧洲泌尿外科学会肾癌指南：2022 年更新版。

Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.帕唑帕尼和帕博利珠单抗联合治疗晚期肾细胞癌患者的 I/II 期研究评估安全性和疗效。

Clin Genitourin Cancer. 2021 Oct;19(5):434-446. doi: 10.1016/j.clgc.2021.04.007. Epub 2021 Apr 20.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。

N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。

N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.

Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications.肾细胞癌对酪氨酸激酶抑制剂耐药的表观遗传改变：从机制到临床应用

Front Genet. 2021 Jan 12;11:562868. doi: 10.3389/fgene.2020.562868. eCollection 2020.

The immunology of renal cell carcinoma.肾细胞癌的免疫学。

Nat Rev Nephrol. 2020 Dec;16(12):721-735. doi: 10.1038/s41581-020-0316-3. Epub 2020 Jul 30.

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.PBRM1 缺失定义了一种非免疫原性肿瘤表型，与肾细胞癌中检查点抑制剂耐药相关。

Nat Commun. 2020 May 1;11(1):2135. doi: 10.1038/s41467-020-15959-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验